Saturday 17 October 2026
Export HLN’s income statement to Excel — free account
Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
10.13
0.19
+1.91%
Follow HLN
| Jun '26 | Jun '25 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | — |
+6 more TTM periods Free account |
|
| 0.00% | 0.00% | 11.68% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow |
4,551.19 | 5,158.36 | — | 4,671.99 | |
Capital Expenditures |
(222.13) | (765.53) | — | (733.99) | |
| Other line items | |||||
Cash ROIC |
13.29% | 15.35% | — | 14.19% | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | (0.23) | — | |
Research and Development Expense of Revenue |
— | — | 2.55% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 38.11% | — | |
Share Based Compensation of Revenue |
— | — | 0.00% | — | |
Interest Coverage |
— | — | 8.13 | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.33 | 0.42 | — | 0.41 | |
Capex/Depreciation |
(0.26) | (0.79) | — | (0.81) | |
Revenue per Share |
— | — | 0.00 | — | |
Operating CF per Share |
0.00 | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates